Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NOVA's XANTHINE R&D PROGRAM COULD REACH CLINICAL STAGE WITHIN 12 MONTHS

Executive Summary

NOVA's XANTHINE R&D PROGRAM COULD REACH CLINICAL STAGE WITHIN 12 MONTHS either in the cardiotonic, cognition activator, or anti-asthmatic areas, Solomon Snyder, MD, chairman of Nova's scientific board, predicted May 21 at the Alex Brown Health Care seminar in Baltimore. With "85 xanthines patented and licensed to Nova" from Johns Hopkins, Snyder noted: "We feel confident that we will be ready with one of these agents for submission to FDA for an IND in the next 12 months." Noting that both theophylline and caffeine are in the xanthine group, Snyder postulated, "If you could tailor-make a theophylline derivative xanthine . . . targeted for one receptor sub-type, that is unique, to work in heart, lung, or brain, you might have a more efficacious drug. If you have a derivative of caffeine which would not cause cardiac effects, didn't cause palpitations, didn't cause diuresis, you might have a drug that would be a very useful stimulant of potential value as a cognition activator." Snyder also reported that the firm may be nearing human testing with a long-acting opiate agonist. Snyder claimed that Nova has several opiate compounds under study that "will act at least 24 hours without any tolerance . . . and with less respiratory depression" than currently marketed opiate compounds. Commenting on potential partnership arrangements, Nova President Donald Stark described Nova's ideal partner as a company "with a worldwide presence in the markets in which we work . . . [with] a good time record in getting these compounds through the FDA approval process and to the marketplace." In addition, Stark said that Nova is looking for a firm which would be willing to support development work as well as pay royalties once a product reached the marketplace. He added that Nova "recently signed" a letter of intent with an undisclosed firm and expects to finalize the agreement "shortly."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel